Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer

Jun Yang, Casey E. Bohl, Vipin A. Nair, Suni M. Mustafa, Soo Hong Seoung, Duane Miller, James T. Dalton

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Proper management of prostate cancer patients is highly dependent on the spread of the disease. High expression levels of the androgen receptor (AR) in prostate tumor offer a target for identifying cancer metastasis. We investigated the use of nonsteroidal AR ligands for receptor-mediated imaging as a diagnostic tool for prostate cancer staging. Compound S-26 [S-3-(4- fluorophenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-iodophenyl)-propionamide]was identified from a series of iodinated ether-linked derivatives of bicalutamide due to its high-AR binding affinity of 3.3 nM (which is similar to testosterone and ∼25% of the binding affinity of dihydrotestosterone) in an in vitro competitive binding assay using rat prostate cytosol. Furthermore, S-26 exhibited a greater binding affinity (Ki = 4.4 nM) in a whole-cell binding assay using COS-7 cells transfected with human AR than testosterone (Ki = 32.9 nM) and dihydrotestosterone (Ki = 45.4 nM). We also confirmed that sex hormone-binding globulin (SHBG), a plasma protein that binds steroids with high affinity, does not bind with S-26. Cotransfection studies with the estrogen, progesterone, and glucocorticoid receptor indicated that S-26 does not cross-react with other members of the steroid hormone receptor family. The nonsteroidal structure, high-AR binding affinity, specificity, and lack of binding to SHBG indicate that S-26 exhibits favorable properties for further development as an imaging agent for prostate cancer.

Original languageEnglish (US)
Pages (from-to)402-408
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume317
Issue number1
DOIs
StatePublished - Apr 1 2006

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Pharmacology
Ligands
Sex Hormone-Binding Globulin
Dihydrotestosterone
Testosterone
Prostate
Competitive Binding
Steroid Receptors
Neoplasm Staging
COS Cells
Glucocorticoid Receptors
Progesterone Receptors
Estrogen Receptors
Ether
Cytosol
Blood Proteins
Neoplasms
Steroids

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. / Yang, Jun; Bohl, Casey E.; Nair, Vipin A.; Mustafa, Suni M.; Seoung, Soo Hong; Miller, Duane; Dalton, James T.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 317, No. 1, 01.04.2006, p. 402-408.

Research output: Contribution to journalArticle

Yang, Jun ; Bohl, Casey E. ; Nair, Vipin A. ; Mustafa, Suni M. ; Seoung, Soo Hong ; Miller, Duane ; Dalton, James T. / Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. In: Journal of Pharmacology and Experimental Therapeutics. 2006 ; Vol. 317, No. 1. pp. 402-408.
@article{85177277126242d78452527fe71e548b,
title = "Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer",
abstract = "Proper management of prostate cancer patients is highly dependent on the spread of the disease. High expression levels of the androgen receptor (AR) in prostate tumor offer a target for identifying cancer metastasis. We investigated the use of nonsteroidal AR ligands for receptor-mediated imaging as a diagnostic tool for prostate cancer staging. Compound S-26 [S-3-(4- fluorophenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-iodophenyl)-propionamide]was identified from a series of iodinated ether-linked derivatives of bicalutamide due to its high-AR binding affinity of 3.3 nM (which is similar to testosterone and ∼25{\%} of the binding affinity of dihydrotestosterone) in an in vitro competitive binding assay using rat prostate cytosol. Furthermore, S-26 exhibited a greater binding affinity (Ki = 4.4 nM) in a whole-cell binding assay using COS-7 cells transfected with human AR than testosterone (Ki = 32.9 nM) and dihydrotestosterone (Ki = 45.4 nM). We also confirmed that sex hormone-binding globulin (SHBG), a plasma protein that binds steroids with high affinity, does not bind with S-26. Cotransfection studies with the estrogen, progesterone, and glucocorticoid receptor indicated that S-26 does not cross-react with other members of the steroid hormone receptor family. The nonsteroidal structure, high-AR binding affinity, specificity, and lack of binding to SHBG indicate that S-26 exhibits favorable properties for further development as an imaging agent for prostate cancer.",
author = "Jun Yang and Bohl, {Casey E.} and Nair, {Vipin A.} and Mustafa, {Suni M.} and Seoung, {Soo Hong} and Duane Miller and Dalton, {James T.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1124/jpet.105.094334",
language = "English (US)",
volume = "317",
pages = "402--408",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer

AU - Yang, Jun

AU - Bohl, Casey E.

AU - Nair, Vipin A.

AU - Mustafa, Suni M.

AU - Seoung, Soo Hong

AU - Miller, Duane

AU - Dalton, James T.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Proper management of prostate cancer patients is highly dependent on the spread of the disease. High expression levels of the androgen receptor (AR) in prostate tumor offer a target for identifying cancer metastasis. We investigated the use of nonsteroidal AR ligands for receptor-mediated imaging as a diagnostic tool for prostate cancer staging. Compound S-26 [S-3-(4- fluorophenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-iodophenyl)-propionamide]was identified from a series of iodinated ether-linked derivatives of bicalutamide due to its high-AR binding affinity of 3.3 nM (which is similar to testosterone and ∼25% of the binding affinity of dihydrotestosterone) in an in vitro competitive binding assay using rat prostate cytosol. Furthermore, S-26 exhibited a greater binding affinity (Ki = 4.4 nM) in a whole-cell binding assay using COS-7 cells transfected with human AR than testosterone (Ki = 32.9 nM) and dihydrotestosterone (Ki = 45.4 nM). We also confirmed that sex hormone-binding globulin (SHBG), a plasma protein that binds steroids with high affinity, does not bind with S-26. Cotransfection studies with the estrogen, progesterone, and glucocorticoid receptor indicated that S-26 does not cross-react with other members of the steroid hormone receptor family. The nonsteroidal structure, high-AR binding affinity, specificity, and lack of binding to SHBG indicate that S-26 exhibits favorable properties for further development as an imaging agent for prostate cancer.

AB - Proper management of prostate cancer patients is highly dependent on the spread of the disease. High expression levels of the androgen receptor (AR) in prostate tumor offer a target for identifying cancer metastasis. We investigated the use of nonsteroidal AR ligands for receptor-mediated imaging as a diagnostic tool for prostate cancer staging. Compound S-26 [S-3-(4- fluorophenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-iodophenyl)-propionamide]was identified from a series of iodinated ether-linked derivatives of bicalutamide due to its high-AR binding affinity of 3.3 nM (which is similar to testosterone and ∼25% of the binding affinity of dihydrotestosterone) in an in vitro competitive binding assay using rat prostate cytosol. Furthermore, S-26 exhibited a greater binding affinity (Ki = 4.4 nM) in a whole-cell binding assay using COS-7 cells transfected with human AR than testosterone (Ki = 32.9 nM) and dihydrotestosterone (Ki = 45.4 nM). We also confirmed that sex hormone-binding globulin (SHBG), a plasma protein that binds steroids with high affinity, does not bind with S-26. Cotransfection studies with the estrogen, progesterone, and glucocorticoid receptor indicated that S-26 does not cross-react with other members of the steroid hormone receptor family. The nonsteroidal structure, high-AR binding affinity, specificity, and lack of binding to SHBG indicate that S-26 exhibits favorable properties for further development as an imaging agent for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33645114469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645114469&partnerID=8YFLogxK

U2 - 10.1124/jpet.105.094334

DO - 10.1124/jpet.105.094334

M3 - Article

VL - 317

SP - 402

EP - 408

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -